Uniqure (NASDAQ:QURE) Stock Price Up 0.3%

Uniqure NV (NASDAQ:QURE)’s stock price shot up 0.3% during trading on Wednesday . The stock traded as high as $65.61 and last traded at $64.08, 21,464 shares changed hands during mid-day trading. A decline of 94% from the average session volume of 341,411 shares. The stock had previously closed at $63.92.

A number of equities analysts recently commented on the stock. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Thursday, November 28th. Goldman Sachs Group began coverage on Uniqure in a research report on Tuesday. They set a “buy” rating and a $98.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating on shares of Uniqure in a research note on Tuesday, September 3rd. ValuEngine downgraded Uniqure from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Sanford C. Bernstein started coverage on shares of Uniqure in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $73.00 price target for the company. Two analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $76.00.

The company has a fifty day simple moving average of $50.73 and a two-hundred day simple moving average of $57.66. The company has a debt-to-equity ratio of 0.19, a current ratio of 14.33 and a quick ratio of 14.33. The company has a market capitalization of $2.43 billion, a P/E ratio of -27.59 and a beta of 0.79.

Uniqure (NASDAQ:QURE) last announced its earnings results on Monday, October 28th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.23. Uniqure had a negative return on equity of 51.12% and a negative net margin of 1,670.86%. The firm had revenue of $1.05 million during the quarter, compared to analysts’ expectations of $2.24 million. Equities analysts anticipate that Uniqure NV will post -2.98 earnings per share for the current year.

In related news, VP Alexander Edward Kuta III sold 4,000 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $47.26, for a total transaction of $189,040.00. Following the completion of the transaction, the vice president now owns 30,578 shares of the company’s stock, valued at approximately $1,445,116.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $47.31, for a total value of $378,480.00. The disclosure for this sale can be found here. Insiders sold 40,769 shares of company stock valued at $1,945,826 over the last 90 days. 2.91% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of QURE. Griffin Asset Management Inc. acquired a new position in Uniqure during the 2nd quarter valued at $39,000. US Bancorp DE raised its position in shares of Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 427 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new position in shares of Uniqure during the second quarter valued at about $78,000. Botty Investors LLC acquired a new position in shares of Uniqure during the second quarter valued at about $78,000. Finally, Aperio Group LLC bought a new stake in shares of Uniqure in the second quarter valued at about $83,000. Institutional investors own 72.56% of the company’s stock.

About Uniqure (NASDAQ:QURE)

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: Support Level

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.